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ABSTRACT 18 
Rare non-epithelial ovarian neoplasms have posed management challenges for many years. 19 
Their rarity means that most specialist practitioners will see one such case every several 20 
years, and most generalists may never see a case. The first step in management is to 21 
establish the correct diagnosis and this may necessitate specialist pathology review. Here, 22 
we review recent developments in the pathology, genetics and treatment of small cell 23 
carcinoma of the ovary, hypercalcemic type (SCCOHT) and sex cord-stromal tumours. 24 
Pathologically, these tumours often display morphological overlap with other neoplasms; 25 
for example, SCCOHT overlaps with many other “small round blue cell” tumours. Specific 26 
immunohistochemical stains, while useful, may not always be definitive. The discovery of 27 
somatic mutations in FOXL2 (adult granulosa cell tumours) and germline and somatic 28 
mutations in DICER1 (Sertoli-Leydig cell tumours) and SMARCA4 (SCCOHT) have 29 
demonstrated the value of molecular investigation as an adjunct to traditional 30 
histopathological approaches. In addition, the presence of germline mutations in a 31 
significant proportion of some of these neoplasms points to the need for genetic counselling 32 
and testing, offering the prospect of prevention and early diagnosis. Treatment of these rare 33 
tumours, as a group, should be on the basis of sound oncological principles, given that level 34 
1 evidence will almost always be lacking. The rationale for experimental therapies must be 35 
clearly established. In view of the complex issues involved in the management of these 36 
conditions, expert opinion in pathology, genetics and treatment may be essential to offer 37 
the patient and her family the best chance of a good outcome. 38 
 39 
 40 
  41 
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INTRODUCTION 42 
The various neoplasms covered in this review all comprise non-epithelial tumours and 43 
mainly, but not exclusively, those in the sex cord-stromal category. Previously there was 44 
little known regarding the underlying molecular abnormalities in the neoplasms discussed 45 
but in recent years there have been significant advances regarding this. This review is aimed 46 
at practitioners in medical genetics, gynaecological oncology, pathology and allied 47 
specialties. The main purpose of this review is not to review all that is known about the 48 
various tumour entities we discuss, but rather draw attention to the most recent 49 
developments, and to show how an inter-disciplinary model of case management, involving 50 
representatives from genetics, pathology, radiation and medical oncology and gynecology-51 
oncology can be invaluable in managing problematic cases. 52 
 53 
Each tumour will be discussed in detail, but by way of introduction and summary, here we 54 
list 15 general points from the perspective of a pathologist, geneticist and oncologist. 55 
1 These are all rare or uncommon neoplasms such that it is possible that an individual 56 
pathologist or an oncologist may not even see one in his/ her diagnostic practice in 57 
their working life. 58 
2 Many of these neoplasms and those in the differential diagnosis occur predominantly 59 
in young women, can be aggressive and require specific chemotherapeutic agents 60 
making a correct diagnosis imperative. 61 
3 Given the rarity of these neoplasms, specialist review and confirmation of the 62 
diagnosis by an expert gynaecological pathologist is advised. 63 
4 These neoplasms tend to exhibit morphological overlap with other tumours; for 64 
example, the morphological features of small cell carcinoma of the ovary, 65 
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hypercalcemic type (SCCOHT) overlap with a wide variety of other “small round blue 66 
cell neoplasms” and Sertoli-Leydig cell tumours (SLCTs) may exhibit significant 67 
morphological overlap with other sex cord-stromal tumours (SCSTs) and also epithelial 68 
neoplasms. 69 
5 Immunohistochemical markers while of use in diagnosing a SCST are of no value in 70 
distinguishing between the various neoplasms in this group. 71 
6 Molecular investigation may in some cases be essential in establishing a diagnosis. 72 
7 Specific immunohistochemical markers may aid greatly in diagnosis; for example, 73 
SMARCA4 (BRG1) immunohistochemistry in the diagnosis of SCCOHT. 74 
8 Establishing a diagnosis of some of the neoplasms discussed should result in 75 
consideration of a familial tumour syndrome which may require germline mutation 76 
analysis and ultimately result in screening of family members. 77 
9 Genetic counselling should be considered for some SCSTs (for example SLCTs) and all 78 
SCCOHT as up to 50% of these tumours may arise in mutation carriers. 79 
10 Little is known about the penetrance (age-dependent risk) for most of the conditions 80 
covered here, so consultation with experts is recommended. 81 
11 Sequencing of both blood and tumour DNA may be of value in helping to determine 82 
risks to both the patient and her relatives. 83 
12 While all in oncology are committed to the delivery of treatments that are “evidence-84 
based”, to have Level 1 evidence from randomised trials as the sole arbiter of the 85 
management of patients with rare tumours is not only an impossibility, it is at best an 86 
absurdity and at worst discriminatory. 87 
13 For slowly evolving tumours, repeat early surgery for relapses is more important than 88 
systemic therapy and should be instituted at a time of balance between too early for 89 
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small disease and too late when extensive, and hence, high-risk, surgery becomes 90 
necessary.  91 
14 If the tumours show aggressive growth, a suitable chemotherapeutic regimen should 92 
be administered, but for two cycles only before evaluation, preferably including 93 
positron emission tomography; all chemotherapy should be stopped immediately if 94 
refractory to two lines or remissions are very short-lived.  95 
15 Targeted therapy e.g. hormone, anti-angiogenic, checkpoint immunotherapy and 96 
molecular targeting must have proven biological rationale e.g. ER positive, VEGFR 97 
known to be present, increased neo-antigen load, EGFR expression. The rules for 98 
assessment of response to targeted therapy should be the same as for traditional 99 
chemotherapy. 100 
 101 
 102 
 103 
 104 
 105 
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 111 
 112 
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SMALL CELL CARCINOMA OF OVARY, HYPERCALCEMIC TYPE (SCCOHT) 114 
Clinical features of SCCOHT 115 
SCCOHT is a rare tumour, with less than 500 cases reported in the world literature. Until 116 
2014, little was known of its etiology, and its rarity made it difficult to study from an 117 
epidemiological perspective. As a tumour, SCCOHT has several notable features. Firstly, it 118 
affects young females; the youngest reported patient is 14 months[1] and the mean age at 119 
diagnosis is approximately 25 years[2]. Secondly, it is associated with a very poor outcome; 120 
even in early-stage disease only about one-third of affected women survive 5 years. Our 121 
recent analysis of all available cases[3] suggests that if treatment can prevent relapse within 122 
5 years of diagnosis, then cure is very likely. Thirdly, SCCOHT is associated with 123 
hypercalcemia in approximately two thirds of cases[2]. 124 
 125 
Pathology of SCCOHT 126 
In a large majority of cases, the tumour is unilateral, although familial cases may be 127 
bilateral.  Grossly these are usually large predominantly solid white or cream coloured 128 
neoplasms, often with cystic foci and areas of haemorrhage and necrosis. 129 
 130 
The histological features are typically of a relatively monotonous population of tumour cells 131 
with various architectural patterns set in a generally inconspicuous stroma[4].  There is 132 
usually predominantly a diffuse sheeted architecture but the neoplastic cells also 133 
occasionally grow in nests, cords or trabeculae.  Follicle-like structures containing 134 
eosinophilic, or more uncommonly basophilic, fluid are present in most cases (figure 1a); 135 
these are a characteristic histological feature but are not pathognomonic since they are 136 
seen in some other neoplasms which are in the differential of SCCOHT[2, 4].  The tumour 137 
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cells usually have minimal cytoplasm resulting in a “small round blue cell” appearance. In 138 
approximately 40% of cases, a variably prominent component of large cells with abundant 139 
eosinophilic cytoplasm is present.  The large cells typically contain abundant glassy 140 
eosinophilic cytoplasm with eccentric large pale nuclei with prominent nucleoli, resulting in 141 
a rhabdoid appearance[4].  When the large cells predominate or are exclusive, the tumour is 142 
rather confusingly referred to as the large cell variant of SCCOHT.   143 
 144 
Genetic Susceptibility and Molecular Events in SCCOHT 145 
Until recently, little was known regarding the histogenesis of SCCOHT and in the 2014 World 146 
Health Organization (WHO) Classification, it is included in the category of miscellaneous 147 
neoplasms[5]. In the last few years, four groups published papers showing that both 148 
germline and somatic mutations in the gene SMARCA4, encoding an ATPase containing 149 
member of the chromatin-remodelling family of proteins, are present in nearly all cases of 150 
SCCOHT (reviewed in ref[6]). This was a critical breakthrough, because as discussed 151 
elsewhere, SCCOHT can be very difficult to diagnose. The biallelic deleterious (usually 152 
predicted to be protein-truncating) mutations in most cases of SCCOHT result in loss of 153 
expression of SMARCA4 within the tumour cells. The significance of this is discussed further 154 
below.  155 
 156 
What is very unusual about the genomics of SCCOHT is that SMARCA4 is the only recurrently 157 
mutated gene in this tumour, and moreover very few other genes are mutated at all in 158 
these neoplasms[6]. A recent study has illustrated this by comparing the mutation profile of 159 
high grade serous carcinoma of the fallopian tube/ovary with SCCOHT; these two tumours 160 
have very different mutational and epigenomic profiles[7]. Interestingly, the tumour that 161 
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SCCOHT seems to most resemble from a pathological and molecular viewpoint is the 162 
pediatric brain tumour, atypical teratoid/rhabdoid tumour (AT/RT)[7]. SCCOHT is in no way 163 
genetically related to other tumours called small cell carcinoma, such as small cell lung 164 
carcinoma and it is clear from the recent molecular studies that it is not an epithelial 165 
neoplasm[6]. 166 
 167 
It is uncertain what proportion of SCCOHT are attributable to germline SMARCA4 mutations, 168 
but the number may be as high as two-fifths (Witkowski et al, manuscript submitted). This 169 
means that all females with SCCOHT should be referred to a genetics service. The risk for 170 
SCCOHT in carriers of germline SMARCA4 mutations is not known, but it is likely to be at 171 
least 20% and possibly much higher. Ascertainment bias and the rarity of the condition 172 
make it difficult to provide precise estimates. The question of whether to offer preventive 173 
oophorectomy to young carriers of SMARCA4 mutations is a challenging area[8], especially 174 
since there are no data to suggest that ovarian surveillance is effective. 175 
 176 
Immunohistochemistry of SCCOHT 177 
Up until recently there were no specific immunohistochemical markers of SCCOHT[9-12]. 178 
Given the discovery that SMARCA4 is mutated in almost all cases of SCCOHT[6], this has 179 
resulted in the development of antibodies which are useful in diagnosis and in the 180 
distinction from the many mimics. There is loss of SMARCA4 (BRG1) immunoreactivity 181 
secondary to mutation in almost all cases of SCCOHT (figure 1b), although a very small 182 
minority exhibit retention of nuclear immunoreactivity; occasional tumours exhibit loss of 183 
SMARCB1 (INI1) rather than SMARCA4[13, 14]. Positive staining of endothelial, stromal and 184 
inflammatory cells acts as a positive internal control and this should be present before 185 
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accepting loss of staining in the tumour cells as indicative of SCCOHT. Although there can be 186 
heterogeneity of staining in some other neoplasms in the differential diagnosis, there is 187 
usually at least focal retention of nuclear immunoreactivity. Some ovarian clear cell 188 
carcinomas exhibit loss of SMARCA4 staining but these do not enter into the differential 189 
diagnosis of SCCOHT[13, 14]. A single ovarian malignant melanoma has been reported to 190 
exhibit loss of SMARCA4 staining[14]. Since this is a neoplasm which may enter into the 191 
differential diagnosis of SCCOHT, this represents a potential diagnostic pitfall. However, the 192 
recent finding that dual loss of both SMARCA4 (BRG1) and SMARCA2 (BRM) protein 193 
expression is highly specific for SCCOHT[15] should mean that such pitfalls can now be 194 
avoided. 195 
 196 
Differential Diagnosis of SCCOHT  197 
SCCOHT is the prototypical ovarian neoplasm composed predominantly or exclusively of 198 
small round cells with scant cytoplasm (so-called “small round blue cell tumour”). The 199 
differential diagnosis of ovarian small round blue cell tumours is wide (table 1) and 200 
pathologists commonly struggle with these neoplasms due to their rarity and overlapping 201 
morphology and immunohistochemistry[16, 17]. Many of these neoplasms occur 202 
predominantly in young women, are highly aggressive and require specific 203 
chemotherapeutic agents making a correct diagnosis imperative. In diagnosing the various 204 
tumour types, immunohistochemistry and molecular studies may be of value. While typical 205 
SCCOHT is part of the differential diagnosis of a small round blue cell tumour, the large cell 206 
variant may be confused with a variety of neoplasms composed of large cells such as 207 
undifferentiated carcinoma and malignant melanoma. It should be noted that the WHO 208 
2014 Classification includes a category of ovarian small cell carcinoma of pulmonary type[5, 209 
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18]; this is a small cell carcinoma of neuroendocrine type (similar to those occurring in the 210 
lung and many other organs) and is in no way related to SCCOHT, although the similar 211 
terminology often results in confusion. 212 
 213 
Treatment of SCCOHT  214 
A general approach to the management of rare tumours is shown in box 1. Small cell 215 
carcinoma of the lung and indeed small cell tumours at other sites are generally sensitive to 216 
chemotherapy, particularly platinum-based regimens. SCCOHT is no exception and in many 217 
ways behaves very similarly to small cell carcinoma of the lung in that response rates are 218 
high but relapse is frequently seen. Stage 1 tumours are potentially curable whereas few 219 
patients with advanced stage disease survive. There are three controversies in the 220 
management of patients with early stage SCCOHT: firstly, the extent of surgery, secondly 221 
which chemotherapy regimen to use and finally whether or not adjuvant radiotherapy has a 222 
part to play.   223 
 224 
The extent of surgery at presentation is a considerable issue as many of these patients are 225 
young and wish to preserve fertility. Usually in a young female with tumour seemingly 226 
confined to one ovary, fertility-sparing surgery, for example unilateral salpingo-227 
oophorectomy and omentectomy, is performed following complete surgical staging. Most 228 
oncologists would administer adjuvant platinum-based chemotherapy following surgery. A 229 
major question, particularly in patients who wish to preserve their fertility, is whether or not 230 
radiotherapy is given adjuvantly and whether that radiotherapy is to the pelvis alone, pelvis 231 
and para-aortic area or the whole abdominal-pelvic region. Clearly pelvic radiotherapy is 232 
associated with gonadal failure and therefore to perform fertility-sparing surgery when 233 
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pelvic radiotherapy in the adjuvant setting is being contemplated is not in our view, a logical 234 
strategy.  235 
 236 
A review of the experience at the MD Anderson has recently been published and this sets 237 
out their experience which very much mirrors that of these authors[19]. The commonest 238 
adjuvant chemotherapy used is a combination of platinum and etoposide. Our practice is to 239 
use BEP (bleomycin, etoposide, cisplatin) but other platinum-based regimens which are a 240 
variation on this have been used and occasionally carboplatin and paclitaxel is used. Some 241 
patients in the MD Anderson series received adjuvant radiotherapy as well as 242 
chemotherapy. Interestingly, in this series only 1 of the 12 long term survivors (The disease 243 
stages of these 12 patients were: 8 stage I, 2 stage II and 2 stage III) received no adjuvant 244 
treatment at all.  The other 11 long term survivors all received adjuvant chemotherapy with 245 
a minority also being treated with radiotherapy after chemotherapy. These data suggest 246 
that radiotherapy may not be an essential addition to adjuvant chemotherapy in patients 247 
with early stage disease (see below).   248 
 249 
However, there are also data to suggest that radiotherapy does have a part to play. Harrison 250 
and colleagues[20] analysed the results in 10 patients with stage 1 disease who had received 251 
BEP chemotherapy Five of six patients who received adjuvant radiotherapy after 252 
chemotherapy were disease-free whereas only one of four patients who did not receive 253 
adjuvant radiotherapy following BEP survived. The long term morbidity of radiotherapy on 254 
bowel and sexual function needs to be addressed in these patients during the consent 255 
process prior to the instigation of this treatment.    256 
 257 
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The arguments relating to the use of radiotherapy along with chemotherapy and perhaps 258 
surgery are completely different in patients whose disease has relapsed. It is the view of 259 
these authors that maximal therapy, including all 3 modalities, is justified because the risks 260 
of not being cured are extremely high when SCCOHT relapses. 261 
 262 
OVARIAN SEX CORD-STROMAL TUMOURS (SCSTs) 263 
Ovarian SCTS comprise a heterogeneous group of neoplasms, both benign and malignant 264 
(table 2). There may be considerable morphological overlap between the various SCSTs and 265 
also between SCSTs and a variety of non-sex cord-stromal tumours such that pathologists 266 
often struggle with the diagnosis and immunohistochemistry is often useful in diagnosis. 267 
With selected tumour types, we discuss the underlying genetic susceptibility and associated 268 
molecular abnormalities but we start this section with a general point regarding the role of 269 
immunohistochemistry in ovarian SCSTs. 270 
 271 
IMMUNOHISTOCHEMISTRY OF OVARIAN SEX CORD-STROMAL TUMOURS 272 
While immunohistochemistry is useful in diagnosing a SCST, it is of limited or no value in 273 
distinguishing between the various neoplasms in this category. Probably the best known 274 
markers of ovarian SCST are inhibin and calretinin, the former being more specific[21-27]. 275 
Although inhibin is positive in a high percentage of SCSTs, some cases are negative. This may 276 
shake the confidence of the pathologist and it is stressed that a diagnosis of a SCST can be 277 
confidently made in the absence of inhibin immunoreactivity. Other markers which may be 278 
positive in this group of neoplasms are steroidogenic factor 1 (SF1), FOXL2 (discussed later), 279 
CD56, CD99, melan A, CD10, Mullerian inhibiting substance and WT1[21-27]. However, all of 280 
these have limitations with regard to specificity and/or sensitivity and are of relatively 281 
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limited value in diagnosis. In the distinction between a SCST and an epithelial neoplasm, 282 
epithelial membrane antigen (EMA) is very useful since this is positive in most epithelial 283 
neoplasms but almost invariably negative in SCSTs. 284 
 285 
OVARIAN GRANULOSA CELL TUMOUR 286 
There are two distinct types of ovarian granulosa cell tumour, namely adult granulosa cell 287 
tumour (AGCT) and juvenile granulosa cell tumour (JGCT). Although AGCTs occur most 288 
commonly in the perimenopausal and early postmenopausal years and JGCTs in the first 289 
three decades, there is overlap in that AGCTs may occur in younger patients and JGCTs in 290 
older patients. It is stressed that the distinction between AGCT and JGCT is made on the 291 
basis of the morphological features and not the patient age.  292 
 293 
ADULT GRANULOSA CELL TUMOUR 294 
Clinical Features of AGCT 295 
AGCT is the most common malignant ovarian SCST, although it accounts for only 1-2% of all 296 
ovarian neoplasms and approximately 5% of ovarian malignancies[28]. Presentation is 297 
usually with symptoms related to an ovarian mass but some patients present with hormonal 298 
manifestations, most commonly oestrogenic (such as abnormal uterine bleeding) but 299 
occasionally androgenic or progestogenic. Some patients present with pain due to tumour 300 
torsion or rupture. The vast majority of AGCTs are stage I at presentation and have a good 301 
long term survival, although recurrence is common. The overall 10 year survival for stage I 302 
neoplasms is in the region of 85 to 95%[29]. Recurrences may be multiple (in number and 303 
time) and often are detected many years following removal of the primary ovarian 304 
neoplasm; it is not uncommon for tumours to recur in excess of 10 or even 20 years 305 
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following initial surgical removal. The most important prognostic factor is tumour stage. 306 
However, almost all AGCTs are stage I at diagnosis (in older case series with a high incidence 307 
of advanced AGCTs, it is likely that many were misdiagnosed) and currently there are no 308 
features which predict with any reliability which stage I AGCTs are likely to recur and would 309 
be candidates for adjuvant therapy following surgical removal. The one possible exception is 310 
tumour rupture which has been shown to be a factor predicting tumour recurrence in the 311 
few studies where this has been examined[29]. Most patients with tumour recurrence will 312 
eventually die of disease. A recently published large single-centre retrospective analysis has 313 
shown that in AGCTs, surgical stage was the only independent factor for the progression-314 
free survival[30]. 315 
 316 
Pathology of AGCT 317 
Histologically AGCT is characterized by the presence of regular cells with ovoid or round 318 
nuclei containing pale chromatin and sometimes nuclear grooves (figure 1c); the cytoplasm 319 
is usually scant with the exception of luteinized variants. Although nuclear grooves have 320 
been considered a characteristic feature of AGCT, they are not seen in every case and are 321 
often not prominent and the pathologist should not rely on the presence of these to make a 322 
diagnosis of AGCT; moreover, nuclear grooves are seen in many other neoplasms.  The 323 
tumour cells in AGCT may be arranged in a variety of architectural patterns, which may be 324 
pure or mixed within a particular neoplasm; these include microfollicular, macrofollicular, 325 
trabecular, insular, diffuse (sarcomatoid), watered silk (parallel rows) and gyriform (zigzag 326 
cords).  The best known architectural pattern is the microfollicular Call-Exner body; 327 
however, these are seen in a minority of AGCTs and, like nuclear grooves, their importance 328 
in diagnosis has been overemphasised.  329 
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 330 
Genetic Susceptibility and Molecular Events in AGCT 331 
There is no known genetic susceptibility to AGCT, and there are no reports in the literature 332 
of families with multiple AGCTs. Until recently, there was little known regarding the 333 
underlying somatic molecular events in AGCT but several recent studies have identified a 334 
somatic missense mutation in codon C134W (402C G) of the FOXL2 (forkhead box L2) 335 
gene in approximately 95% of AGCTs[31-33]. The FOXL2 gene encodes a transcription factor 336 
required for ovarian development, in particular granulosa cell function and ovarian follicle 337 
development. FOXL2 mutation is rare in SCSTs other than AGCT[31-33] and it has been 338 
suggested that these may represent misclassified AGCTs. Correct diagnosis of AGCT is 339 
important for prognostication given the potential for late recurrence and metastasis which 340 
is not a feature of other SCSTs. Given that FOXL2 mutation is an extremely sensitive and 341 
quite specific molecular marker of AGCT, testing may be extremely useful in helping to 342 
confirm or refute a diagnosis of AGCT in problematic cases.  343 
 344 
While FOXL2 mutations are largely, but probably not exclusively, restricted to AGCT, many 345 
SCSTs of other types exhibit positive nuclear staining with antibodies against FOXL2. 346 
Therefore, while FOXL2 immunohistochemistry is useful in confirming a SCST since almost all 347 
non-sex cord-stromal tumours are negative, it is of limited value in distinguishing between 348 
the various tumour types[34].  349 
 350 
JUVENILE GRANULOSA CELL TUMOUR 351 
JGCTs may present with symptoms related to an ovarian mass or with hormonal 352 
manifestations such as isosexual precocious puberty[35]. There are differences in clinical 353 
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behaviour between JGCT and AGCT in that the former is less likely to recur or metastasise 354 
but when this does happen it usually occurs early within a few years[35]; this is in contrast 355 
to the propensity of AGCT for late recurrence and metastasis. Hypercalcemia has been 356 
reported in occasional cases[36-38]. 357 
 358 
Almost all JGCTs are unilateral. Most grow as diffuse sheets of tumour cells with 359 
hyperchromatic nuclei and relatively abundant eosinophilic or luteinised cytoplasm. Follicles 360 
of variable size and irregular shape are common containing basophilic or eosinophilic fluid 361 
(figure 1d). There may be abundant mitotic activity and moderate or even severe nuclear 362 
atypia.  363 
 364 
SCCOHT is an important differential diagnostic consideration. Both neoplasms typically 365 
affect the same age group but, in striking contrast to JGCT, SCCOHT follows a highly 366 
aggressive course. Hypercalcaemia is highly suggestive of SCCOHT but is only present in 367 
about two-thirds of cases, and has rarely been reported in JCGT (see above). Conversely, 368 
oestrogenic manifestations point to JGCT but they are not present in all cases.   369 
 370 
Immunohistochemistry is of considerable value in problematic cases since SCCOHT exhibits 371 
loss of nuclear immunoreactivity with SMARCA4 and is often positive with EMA while JGCT 372 
is positive with sex cord markers such as inhibin, negative with EMA and there is retention 373 
of nuclear staining with SMARCA4. 374 
 375 
 376 
 377 
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Genetic Susceptibility and Molecular Events in JGCT 378 
JGCTs occasionally occur in a number of genetic syndromes, such as Olliers disease (multiple 379 
enchondromas)[35, 39-41] and the genetically-identical Maffucci’s syndrome (multiple 380 
enchondromas associated with soft tissue hemangiomas)[42]. Amary et al[43] reported 381 
somatic mosaic IDH1 and IDH2 mutations, nearly always affecting Arg132 of IDH1 or Arg172 382 
of IDH2, in both Olliers disease and Maffucci syndrome, strongly suggesting that the JGCTs 383 
occurring in these patients are similarly caused by somatic mosaic mutations in these two 384 
genes. Somatic DICER1 mutations are occasionally found in JGCT; in one study, one of 14 385 
JGCTs were reported to have somatic “hotspot” DICER1 mutations (see below)[44], but 386 
none were found in 4 JGCTs in another study[45]. Two JGCTs have occurred in patients likely 387 
to carry germline DICER1 mutations[46], but to date no such germline-mutated cases have 388 
been published. 389 
 390 
It is important to note that JGCT is different from AGCT in that FOXL2 mutations are found 391 
only rarely in the former. In one study, “hotspot” activating GNAS mutations (at position 392 
201) were reported in nine of 30 patients with JGCT[47]. Recently, the same group found in-393 
frame tandem activating duplications of exon 3 of AKT1 in 9/16 JGCTs diagnosed under the 394 
age of 15 years[48, 49]. RNA-Seq analysis showed patterns of gene expression supportive of 395 
an important role for this mutation in the pathogenesis of JGCT. Interestingly, this group 396 
also reported the presence of this activating duplication in a FOXL2-negative AGCT[48]. 397 
These findings show that AGCT and JGCT are in general molecularly distinct entities. 398 
 399 
 400 
 401 
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TREATMENT OF AGCT AND JGCT  402 
The mainstay of management of patients with AGCTs is surgery. Fertility-sparing surgery, 403 
following complete surgical staging, is acceptable because the incidence of bilaterality is 404 
below 5%.  405 
 406 
The sensitivity of AGCTs to platinum-based chemotherapy varies from 40-90%. Bleomycin, 407 
Etoposide, cisPlatinum (BEP) chemotherapy is the most commonly used regimen with 408 
response rates as high as 80%, although earlier studies of nonplatinum-based chemotherapy 409 
have shown response rates of 60-70% (reviewed by Kottarathil et al[50]). Taxanes have 410 
been introduced to regimens for AGCTs with response rates similar to BEP in newly 411 
diagnosed patients but there are no randomised data comparing BEP with platinum-412 
paclitaxel combinations. Nonrandomised comparisons in patients with recurrent disease 413 
have suggested that there may be an advantage to BEP, but these results must be 414 
interpreted with great caution. The Gynecologic Oncology Group is currently conducting a 415 
randomized phase II trial of BEP versus carboplatin-paclitaxel in women with ovarian SCSTs 416 
who have not previously received chemotherapy in both the first line and relapsed setting 417 
(GOG 264, NCT01042522). 418 
 419 
Some argue that there is a role for adjuvant chemotherapy in patients with advanced 420 
disease who have their tumour debulked either optimally or sub-optimally. While some 421 
authors have reported no recurrences in early stage disease following adjuvant BEP, it is 422 
clear that patients with early disease can be cured by surgery alone or at least have very 423 
long disease-free intervals. We do not suggest adjuvant chemotherapy for patients with 424 
early stage disease.  Even in patients who have completely resected advanced disease, there 425 
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is a question as to whether or not postoperative chemotherapy should be given because 426 
many patients have slowly evolving tumours and there is merit in adopting a watch and wait 427 
policy to see whether the patient’s tumour behaves in an indolent or aggressive fashion. For 428 
patients with indolent disease, repeated surgery with the institution of chemotherapy only 429 
with bulky disease that cannot be treated surgically, allows the patient to survive longer 430 
with good quality of life without the side effects of chemotherapy. 431 
 432 
Angiogenesis inhibitors have also been used in recurrent disease because of the vascular 433 
nature of these tumours and both response and stabilisation of disease is reported. Another 434 
targeted approach under investigation involves monoclonal antibodies against tumour 435 
necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors. Hormone therapies are 436 
not generally used in the adjuvant setting but do have a role for patients with relapse. 437 
Responses can be obtained and some are durable. The advantage of hormone therapy is the 438 
comparative lack of side effects compared to chemotherapy. There is no clear single 439 
mechanism of action that accounts for the beneficial effect of hormone therapy and most 440 
hormonal agents have shown some effect including medroxyprogesterone acetate, 441 
megestrol, anastrozole, letrozole and gonadotropin-releasing hormone agonists.   442 
 443 
The precise role of radiotherapy is not defined. There are data which suggest an advantage 444 
with adjuvant radiation but the advantage appears to be relatively small and there is always 445 
the issue of the long term side effects of pelvic recurrence. Radiation is best kept in reserve 446 
for incompletely resected or single site non resectable recurrent disease where it can have a 447 
very useful palliative role.  448 
 449 
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The young age of onset and rarity of JGCTs of the ovary make decisions concerning fertility-450 
sparing surgery difficult because some authors have claimed that radical surgery and even 451 
adjuvant radiotherapy and chemotherapy are associated with better outcomes, in particular 452 
high cure rates. However, not all retrospective series have shown this and considerable 453 
caution is required before young women are subjected to radical treatments that will affect 454 
their long term morbidity and quality of life. For stage 1A JGCT, there is no evidence that any 455 
treatment other than fertility-sparing surgery is of benefit and issues that relate to the 456 
administration of adjuvant chemotherapy or radiotherapy should only be considered in 457 
patients with Stage 1C or above disease; for these patients the evidence for adjuvant 458 
treatment is weak. We would not consider pelvic radiation because of its morbidity. 459 
However, for both AGCT and JGCT, in patients with Stage 1C disease some recommend 460 
adjuvant BEP in the presence of other poor prognostic features such as nuclear atypia, high 461 
mitotic index, aneuploidy, age > 40 years, but the significance of these factors is debated; 462 
we would not routinely use them or give adjuvant therapy to patients with a Stage 1C 463 
granulosa cell tumour[51-53]. 464 
 465 
SERTOLI-LEYDIG CELL TUMOURS 466 
Ovarian Sertoli-Leydig cell tumours (SLCTs) occur at all ages but have a propensity to arise in 467 
relatively young patients with a mean age of approximately 25 years. Retiform variants 468 
usually occur in particularly young patients with a mean age of 15 years. Presentation may 469 
be with symptoms related to an ovarian mass or with virilisation. Most tumours are 470 
unilateral and confined to the ovary at diagnosis. The WHO Classification divides SLCTs into 471 
well, moderate (previously referred to as intermediate) and poorly differentiated and 472 
21 
 
retiform variants[5]. Moderate and poorly differentiated and retiform variants may contain 473 
heterologous elements.  474 
 475 
Well differentiated SLCTs are composed of solid or hollow Sertoli cell tubules and variable 476 
numbers of Leydig cells (figure 1e). Moderately differentiated tumours often have a low 477 
power lobulated architecture and are characterized by cellular areas composed of cords, 478 
nests and tubules of immature Sertoli cells. Leydig cells are present which are often most 479 
apparent at the periphery of the cellular aggregates of Sertoli cells. Poorly differentiated 480 
neoplasms contain a significant amount of immature cellular mesenchymal tissue with high 481 
mitotic activity, often resembling an undifferentiated sarcoma. Establishing a diagnosis 482 
relies on the presence of more distinctive patterns of Sertoli cell elements and Leydig cells 483 
which may be revealed by extensive sampling. Retiform SLCTs have a characteristic gross 484 
appearance with large oedematous polyps, often resembling a hydatidiform mole or serous 485 
borderline tumour. The morphological features are of a network of elongated tubules and 486 
cysts, resembling the rete testis.  487 
 488 
Heterologous elements occur in approximately 20% of SLCTs. The most common 489 
heterologous element is intestinal type mucinous epithelium Less common heterologous 490 
elements include rhabdomyoblasts, cartilage, hepatoid elements and foci of carcinoid 491 
tumour 492 
 493 
Genetic Susceptibility and Molecular Events in SLCTs  494 
The most important genetic susceptibility factor for SLCTs is germline DICER1 mutations. In 495 
2011, Rio Frio et al identified different pathogenic germline DICER1 mutations in two 496 
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families containing women with both SLCT and multinodular goitre[54], confirming the 497 
genetic basis of an association that had been noted many years previously. Subsequently, 498 
somatic DICER1 mutations were identified in the SLCTs arising in these germline-mutated 499 
cases[44], as well as somatic mutations in cases where germline DICER1 status was not 500 
known. From this and subsequent studies, it appears that up to 60% of SLCTs carry somatic 501 
mutations in DICER1[44, 55-57]. The prevalence of germline DICER1 mutations in SLCT is not 502 
known, but it may be as high as the somatic mutation frequency, and all patients with SLCT 503 
should be referred to genetics services.  One of the most fascinating aspects of the 504 
mutations seen in SLCTs and other DICER1-related tumours is that they are almost entirely 505 
restricted to exons encoding the RNase IIIb domains of the protein. Moreover, nearly all the 506 
mutations are predicted to not truncate the protein; instead, they are missense mutations 507 
affecting the metal-ion binding residues within the RNase IIIb domain[44]. These mutations 508 
appear to have oncogenic roles[58], and function by altering the balance between 5p and 3p 509 
microRNAs[59, 60], which are the products of DICER1 cleavage of precursor microRNAs[61]. 510 
How these mutations lead to the highly specific, and generally very rare, manifestations of 511 
the DICER1 syndrome is not known.  512 
 513 
While most ovarian SCSTs associated with DICER1 mutations are SLCTs, there are also 514 
occasional reports of JGCT, Sertoli cell tumour, gynandroblastoma and unclassified SCST 515 
harbouring these mutations[56]. While the demonstration of DICER1 mutations in these 516 
various neoplasms may well indicate that mutations occur in SCSTs other than SLCTs, it 517 
should be pointed out that there is significant morphological overlap between tumours in 518 
the SCST category and it is possible that some of these other neoplasms containing DICER1 519 
mutations represent misclassified SLCTs. A recent study of a small number of cases 520 
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suggested that gynandroblastomas (a SCST exhibiting both male and female differentiation) 521 
may encompass two distinct entities at the genetic level, those with a granulosa-like 522 
genotype exhibiting FOXL2 hotspot mutations and those with a SLCT-like DICER1 mutant 523 
genotype[56].  524 
 525 
Treatment of SLCT  526 
Patients with stage 1A well differentiated Sertoli-Leydig tumours do not require adjuvant 527 
therapy and can be managed by fertility-sparing surgery only following complete surgical 528 
staging. Moderately and poorly differentiated SLCTs and higher stage tumours should 529 
probably receive adjuvant chemotherapy if for no other reason that when relapse occurs, 530 
survival is low because relapsed Sertoli-Leydig tumours are incurable and often behave 531 
aggressively[62-64]. 532 
 533 
BEP is one of the most commonly used regimens for these tumours, although other 534 
platinum-based regimens have also been used such as cisplatin-doxorubicin-535 
cyclophosphamide, carboplatin-epirubicin-etoposide, cisplatin-vinblastine-bleomycin and 536 
platinum-taxane.  537 
 538 
OVARIAN SEX CORD TUMOUR WITH ANNULAR TUBULES (SCTAT) 539 
This is an uncommon ovarian neoplasm which occurs either sporadically (most commonly) 540 
or in association with Peutz-Jeghers syndrome (PJS)[65, 66]. Those neoplasms associated 541 
with PJS occur on average at a slightly younger age than sporadic neoplasms. Sporadic 542 
neoplasms are almost always unilateral and present with menstrual irregularities or 543 
symptoms related to an ovarian mass. In contrast, those neoplasms associated with PJS are 544 
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almost always bilateral and multifocal within the same ovary. Often they are incidental 545 
microscopic findings in patients known to have PJS; it has been suggested that microscopic 546 
SCTATs are almost invariably seen in the ovaries of patients with PJS. 547 
 548 
Both PJS-associated and sporadic SCTATs are composed of well circumscribed rounded nests 549 
of cells with punched-out spaces containing hyalinized basement membrane-like material 550 
which may be focally calcified (figure 1f). The nuclei are characteristically located at the 551 
periphery of the nests. Uncommonly, small foci resembling AGCT or Sertoli cell tumour are 552 
present, especially in non-PJS associated cases.  553 
 554 
The prognosis of SCTATs in patients with PJS is excellent with a usual benign clinical course, 555 
although occasional neoplasms have behaved in an aggressive manner[66]. Sporadic SCTATs 556 
have a potential for malignant behaviour and extra-ovarian spread (one fifth of cases) which 557 
cannot be reliably determined by microscopic examination[66].  558 
 559 
When diagnosing a SCTAT, the pathologist should raise the possibility of PJS syndrome; 560 
probably at least a third of all SCTATs occur in the context of PJS[66]. Establishing a 561 
diagnosis allows screening to detect other neoplasms which potentially occur in patients 562 
with PJS, including cervical gastric-type adenocarcinomas. 563 
 564 
Germline mutations in SKT11 are the underlying cause of PJS[67]. Loss of heterozygosity at 565 
19p13.3, including SKT11, is seen in SCTATs associated with PJS[68]. Point mutations in the 566 
SKT11 gene have not been detected in PJS-related or PJS unrelated SCTATs[68] or in SCSTs in 567 
general[69].  The lifetime risk for SCTAT in female STK11 mutation carriers is uncertain. In a 568 
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large retrospective cohort study that included 226 female STK11 carriers, only two ovarian 569 
tumours were recorded[70], suggesting a low risk, whereas a previous meta-analysis found 570 
a risk for ovarian tumours of 21%[71], mandating yearly pelvic ultrasonography[72]. This 571 
could be regarded as unjustified given the excellent prognosis of SCTAT in PJS, and has 572 
recently been rejected as a recommended surveillance strategy[73]. 573 
 574 
CONCLUSIONS 575 
In this review, we have discussed the key pathological, genetic and management aspects of 576 
selected uncommon ovarian non-epithelial tumours. As a group, they often present 577 
challenges to both the pathologist, from a diagnostic viewpoint, and to the oncologist from 578 
the treatment perspective. Recent molecular evaluation of patients with these neoplasms 579 
(and the tumours) has resulted in the discovery of somatic and genetic mutations resulting 580 
in important insights which may aid both the pathologist and the oncologist. It is likely that 581 
further molecular characterization of these tumours, combined with innovative randomized 582 
“basket” trials, will lead to the development of specific targeted therapies and significant 583 
improvement in the outcome for the more aggressive tumours in this group, such as 584 
SCCOHT. 585 
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Figures and Tables 821 
Figure 1. SCCOHT composed of sheets of small round blue cells puntuated by many follicle-like 822 
spaces (a). Loss of nuclear immunoreactivity with SMARCA4 (retention of staining in endothelial cells 823 
serves as an internal positive control) is useful in diagnosis of SCCOHT (b). AGCT composed of regular 824 
cells with vesicular nuclei, some containing grooves; microfollicular Call-Exner bodies are present (c). 825 
JGCT composed of cells with abundant cytoplasm arranged in diffuse sheets with intermediate sized 826 
follicles (d). Well differentiated SLCT composed of Sertoli cell tubules with surrounding Leydig cells 827 
with eosinophilic cytoplasm (e). SCTAT composed of well demarcated nests of cells with punched out 828 
spaces containing hyalinized basement membrane-like material (f). 829 
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Table 1: Differential diagnosis of ovarian neoplasms composed of small round blue cells. This is not 831 
an exhaustive list since occasionally other neoplasms may enter into this differential diagnosis. 832 
Primary 
Granulosa cell tumors 
Sertoli-Leydig cell tumor (moderately and poorly differentiated) 
Luteinized thecoma associated with sclerosing peritonitis 
Endometrial stromal sarcoma 
Carcinoid tumor 
Small cell carcinoma, hypercalcaemic type 
Small cell carcinoma, pulmonary type 
Malignant melanoma 
Undifferentiated carcinoma 
Immature teratoma 
Lymphoma/ leukaemia 
Primitive neuroectodermal tumour/ Ewing family of tumors 
Rhabdomyosarcoma 
Undifferentiated sarcoma 
 
Metastatic 
Endometrial stromal sarcoma 
Breast carcinoma 
Intra-abdominal desmoplastic small round cell tumor 
Malignant melanoma 
Carcinoid tumor 
Small cell carcinoma 
Primitive neuroectodermal tumour/ Ewing family of tumors and neuroblastoma 
Rhabdomyosarcoma 
 833 
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Table 2: WHO 2014 Classification of ovarian sex cord-stromal tumours. (a Moderately and poorly 835 
differentiated and retiform variants may contain heterologous elements. b NOS = not otherwise 836 
specified). 837 
 838 
Pure stromal tumours Pure sex cord tumours Mixed sex cord-stromal tumours 
Fibroma Adult granulosa cell tumour Sertoli-Leydig cell tumours (well 
differentiated, moderately 
differentiated, poorly differentiated, 
retiform)a 
Cellular fibroma Juvenile granulosa cell tumour Sex cord-stromal tumours, NOSb 
Thecoma Sertoli cell tumour  
Luteinized thecoma associated 
with sclerosing peritonitis 
Sex cord tumour with annular 
tubules 
 
Fibrosarcoma   
Sclerosing stromal tumour   
Signet-ring stromal tumour   
Microcystic stromal tumour   
Leydig cell tumour   
Steroid cell tumour   
Steroid cell tumour, malignant   
 839 
